证券代码：002653 证券简称：海思科 公告编号：2025-134 海思科医药集团股份有限公司 关于向特定对象发行股票提交募集说明书（注册稿）等 申请文件的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）向特定对象发 行股票的申请已于 2025 年 12 月 18 日获得深圳证券交易所上市审核中心 审核通过，具体内容详见公司于 2025 年 12 月 19 日在巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于向特定对象发行股票申请 获得深圳证券交易所上市审核中心审核通过的公告》（公告编号： 2025-133）。 公司本次向特定对象发行股票事项尚需获得中国证券监督管理委员 会（以下简称"中国证监会"）同意注册后方可实施，最终能否获得中 国证监会同意注册的批复及其时间尚存在不确定性。 公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投 资者审慎决策，关注投资风险。 1 特此公告。 海思科医药集团股份有限公司董事会 2025 年 12 月 23 日 2 根据公司实际情况及 ...

中信证券股份有限公司 关于 海思科医药集团股份有限公司 向特定对象发行A股股票 之 发行保荐书 保荐人（主承销商） 广东省深圳市福田区中心三路8号卓越时代广场（二期）北座 二〇二五年十二月 | 目 求……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 1 | | --- | | 声 明 ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 2 | | 第一节 本次证券发行基本情况 | | 一、保荐人名称 | | 二、项目保荐代表人、协办人及其它项目组成员情况 3 | | 三、发行人情况 | | 四、保荐人与发行人存在的关联关系 | | 五、保荐人内部审核程序和内核意见 . | | 第二节 保荐人承诺事项 | | 第三节 保荐人对本次证券发行上市的保荐结论 | | 一、对本次 ...

中信证券股份有限公司 关于 海思科医药集团股份有限公司 向特定对象发行 A 股股票 之 上市保荐书 3-3-1 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年十二月 海思科医药集团股份有限公司向特定对象发行 A 股股票申请文件 上市保荐书 声 明 本保荐人及保荐代表人根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《证券发 行上市保荐业务管理办法》、《上市公司证券发行注册管理办法》（以下简称"《注 册管理办法》"）等有关法律、行政法规和中国证券监督管理委员会、深圳证券 交易所的规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则和行业自律 规范出具上市保荐书，并保证所出具文件真实、准确、完整。 本上市保荐书中如无特别说明，相关用语与《海思科医药集团股份有限公司 2025 年度向特定对象发行 A 股股票募集说明书》中的含义相同。 海思科医药集团股份有限公司向特定对象发行 A 股股票申请文件 上市保荐书 一、发行人基本情况 （一）发行人基本情况 | 公司名称： | 海思科医药集团股份有限公司 | | | -- ...

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

Core Viewpoint - Company subsidiary, Liaoning Hisun Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the clinical trial application of drug "HSK46575" in combination with Olaparib or Docetaxel and Prednisone for the treatment of prostate cancer [1] Group 1: Drug Development - HSK46575 is a self-developed oral, potent, and highly selective small molecule inhibitor intended for prostate cancer treatment [1] - Preclinical research results indicate that the drug has a clear target, definite efficacy, and good safety profile, showcasing significant development potential [1] - The drug is expected to become an effective treatment for prostate cancer, addressing the current shortage of clinical treatment options [1] Group 2: Regulatory Classification - According to the National Medical Products Administration's announcement on the classification and application requirements for chemical drug registration, HSK46575 is classified as a Class 1 chemical drug [1]

Core Viewpoint - The announcement indicates that the company's subsidiary, Liaoning Hisun Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the clinical trial application of the drug "HSK46575" in combination with Olaparib or Docetaxel and Prednisone for the treatment of prostate cancer [1] Group 1: Drug Development - HSK46575 is a self-developed oral, potent, and highly selective small molecule inhibitor intended for the treatment of prostate cancer [1] - Preclinical research results show that the drug has a clear target, definite efficacy, and good safety profile, indicating high development potential [1] - The drug is expected to become an effective treatment for prostate cancer, addressing the current shortage of clinical treatment options [1] Group 2: Regulatory Classification - According to the National Medical Products Administration's announcement regarding the classification and application requirements for chemical drug registration, HSK46575 is classified as a Class 1 chemical drug [1]

Core Viewpoint - The announcement indicates that the company's subsidiary, Liaoning Hisun Pharmaceutical Co., Ltd., has received a clinical trial application acceptance notice from the National Medical Products Administration for HSK46575 tablets in combination with Olaparib or Docetaxel and Prednisone for the treatment of prostate cancer [1] Group 1 - HSK46575 is a self-developed oral, potent, and highly selective small molecule inhibitor intended for prostate cancer treatment [1] - Preclinical research results show that HSK46575 has a clear target, definite efficacy, and good safety, indicating a broad clinical application prospect [1]

Core Viewpoint - Company Haisco (002653.SZ) has received an acceptance notice from the National Medical Products Administration for its drug HSK46575, which is a small molecule inhibitor developed for the treatment of prostate cancer [1] Group 1: Drug Development - HSK46575 is an orally administered, potent, and highly selective small molecule inhibitor [1] - Preclinical research indicates that the drug has a clear target, definite efficacy, and good safety profile, showcasing its significant development potential [1] - The drug is expected to address the current shortage of effective treatments for prostate cancer, presenting a high benefit/risk ratio for clinical application [1]

证券代码：002653 证券简称：海思科 公告编号：2025-135 海思科医药集团股份有限公司 1 目前临床上对于经新型内分泌治疗（NHA）治疗后耐药的前列腺 癌患者治疗选择非常有限，也尚无针对AR-LBD突变前列腺癌患者的理 想治疗药物，存在较大的未满足临床需求。与大多数靶向药物一样， 单一机制药物治疗最终可能面临单药药效不足、旁路激活或互补性耐 药机制的出现，也给前列腺患者的治疗和预后带来较大的挑战。 HSK46575片是公司自主研发的一种口服、强效和高选择性的小分 子抑制剂，拟用于前列腺癌的治疗。临床前研究结果表明，本品靶点 明确、疗效确切、安全性好，是一款极具开发潜力的小分子药物，临 床应用的效益/风险比高，具有广阔的临床应用前景，有望成为前列 腺癌的有效治疗药物并解决目前临床用药匮乏的难题。根据国家药品 监督管理局关于发布《化学药品注册分类及申报资料要求》的通告 （2020年第44号）中化学药品注册分类的规定，本品属于化学药品1 类。 关于获得创新药 HSK46575 片新增适应症 IND 申请《受 理通知书》的公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， | | --- ...

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The oral treatment landscape for psoriasis has established a dual leadership pattern with TYK2 and IL23 inhibitors, highlighting the potential of companies like Yifang Biopharma, Nocankang, and Haishike [1][16] - The A-share pharmaceutical index has shown a year-to-date increase of 14.49%, while the Hang Seng Healthcare Index has surged by 65.28% [4][9] - The report emphasizes the importance of innovative drugs, with a ranking of preferred sub-industries: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [10][12] Industry Trends - The report notes that the A-share pharmaceutical index has underperformed relative to the CSI 300 index, with a slight decrease of 0.14% this week [4][9] - The report highlights the strong performance of the medical commercial sector (+4.94%) and medical devices (+1.16%) this week, while the chemical pharmaceuticals sector saw a decline of -1.74% [4][9] - The report identifies key companies to watch in the TYK2 space, including Yifang Biopharma and Nocankang, as well as those involved in oral IL23 treatments like Haishike [16][12] Company-Specific Recommendations - Recommended companies in the innovative drug sector include: - Yifang Biopharma - Nocankang - Haishike - Heng Rui Medicine - Bai Jie Shen Zhou - Shi Yao Group - Zai Jian Medicine - Di Zhe Medicine [12][16] - In the CXO and research services sector, recommended companies include: - WuXi AppTec - Hao Yuan Medicine - Aopumai - Kingsray Biotech [12] - For traditional Chinese medicine, companies to focus on include: - Zuo Li Pharmaceutical - Fang Sheng Pharmaceutical - Dong E E Jiao [12] Market Performance - The report indicates that the A-share pharmaceutical index has shown a year-to-date increase of 14.49%, while the Hang Seng Healthcare Index has increased by 65.28% [4][9] - The report also notes that the medical commercial sector has performed well this week, with a gain of 4.94% [4][9]